Citadel Advisors’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $341K | Buy |
75,700
+31,200
| +70% | +$136K | ﹤0.01% | 10178 |
|
|
2025
Q4 | $214K | Sell |
44,500
-8,300
| -16% | -$37.3K | ﹤0.01% | 10904 |
|
|
2025
Q3 | $240K | Buy |
52,800
+16,500
| +45% | +$60.6K | ﹤0.01% | 10857 |
|
|
2025
Q2 | $112K | Buy |
36,300
+10,700
| +42% | +$35.5K | ﹤0.01% | 11242 |
|
|
2025
Q1 | $89.3K | Sell |
25,600
-6,500
| -20% | -$21.7K | ﹤0.01% | 11625 |
|
|
2024
Q4 | $105K | Sell |
32,100
-3,600
| -10% | -$13.2K | ﹤0.01% | 11416 |
|
|
2024
Q3 | $137K | Buy |
35,700
+5,800
| +19% | +$22.2K | ﹤0.01% | 10680 |
|
|
2024
Q2 | $92.4K | Sell |
29,900
-76,800
| -72% | -$230K | ﹤0.01% | 11027 |
|
|
2024
Q1 | $275K | Buy |
106,700
+81,900
| +330% | +$212K | ﹤0.01% | 9649 |
|
|
2023
Q4 | $62K | Buy |
24,800
+1,600
| +7% | +$3.13K | ﹤0.01% | 11553 |
|
|
2023
Q3 | $47.1K | Sell |
23,200
-1,000
| -4% | -$2.1K | ﹤0.01% | 11822 |
|
|
2023
Q2 | $55.7K | Buy |
24,200
+12,100
| +100% | +$31.5K | ﹤0.01% | 11678 |
|
|
2023
Q1 | $36.7K | Sell |
12,100
-55,100
| -82% | -$155K | ﹤0.01% | 12535 |
|
|
2022
Q4 | $157K | Buy |
67,200
+15,800
| +31% | +$37.8K | ﹤0.01% | 10552 |
|
|
2022
Q3 | $98K | Sell |
51,400
-13,400
| -21% | -$31.5K | ﹤0.01% | 11112 |
|
|
2022
Q2 | $176K | Sell |
64,800
-117,500
| -64% | -$301K | ﹤0.01% | 10832 |
|
|
2022
Q1 | $543K | Sell |
182,300
-68,900
| -27% | -$211K | ﹤0.01% | 9188 |
|
|
2021
Q4 | $977K | Buy |
251,200
+29,600
| +13% | +$115K | ﹤0.01% | 8018 |
|
|
2021
Q3 | $951K | Sell |
221,600
-87,500
| -28% | -$292K | ﹤0.01% | 8281 |
|
|
2021
Q2 | $937K | Buy |
309,100
+35,300
| +13% | +$109K | ﹤0.01% | 8532 |
|
|
2021
Q1 | $912K | Buy |
273,800
+22,400
| +9% | +$86.4K | ﹤0.01% | 8344 |
|
|
2020
Q4 | $892K | Buy |
251,400
+195,900
| +353% | +$686K | ﹤0.01% | 7032 |
|
|
2020
Q3 | $174K | Buy |
+55,500
| New | +$169K | ﹤0.01% | 8916 |
|
|
2017
Q1 | – | Sell |
-37,500
| Closed | -$92K | – | 7367 |
|
|
2016
Q4 | $92K | Buy |
37,500
+26,100
| +229% | +$75.9K | ﹤0.01% | 6707 |
|
|
2016
Q3 | $39K | Buy |
+11,400
| New | +$44.5K | ﹤0.01% | 6901 |
|
|
2016
Q1 | – | Sell |
-9,600
| Closed | -$43K | – | 6638 |
|
|
2015
Q4 | $43K | Sell |
9,600
-2,600
| -21% | -$14.3K | ﹤0.01% | 7425 |
|
|
2015
Q3 | $74K | Sell |
12,200
-12,500
| -51% | -$111K | ﹤0.01% | 7246 |
|
|
2015
Q2 | $293K | Sell |
24,700
-7,600
| -24% | -$116K | ﹤0.01% | 5777 |
|
|
2015
Q1 | $564K | Buy |
32,300
+26,100
| +421% | +$535K | ﹤0.01% | 4721 |
|
|
2014
Q4 | $94K | Sell |
6,200
-34,800
| -85% | -$601K | ﹤0.01% | 6687 |
|
|
2014
Q3 | $867K | Buy |
41,000
+34,600
| +541% | +$565K | ﹤0.01% | 3882 |
|
|
2014
Q2 | $84K | Buy |
+6,400
| New | +$90.7K | ﹤0.01% | 6370 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Citadel Advisors's ABUS Position: Q1 2026 in Review
Citadel Advisors increased its Arbutus Biopharma (ABUS) stake by 546% in Q1 2026, buying an estimated $2.5M and bringing the position to 677,138 shares worth $3.05M. The position accounts for ﹤0.01% of the portfolio, ranked #5232.
Citadel Advisors first reported a position in ABUS in Q2 2014 and has held it in 41 quarters since. The position peaked at $6.29M in Q1 2015. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Citadel Advisors held 677,138 shares of Arbutus Biopharma worth $3.05M as of Q1 2026.
- Citadel Advisors bought 572,295 Arbutus Biopharma shares in Q1 2026, an estimated $2.5M.
- Arbutus Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5232 holding.
- Citadel Advisors first reported a position in Arbutus Biopharma in Q2 2014 and has held it in 41 quarters since.
- Citadel Advisors's Arbutus Biopharma position peaked at $6.29M in Q1 2015.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.